Synastra Biotechnology

Synastra Biotechnology is a Türkiye-based gene therapy company established through a collaboration between Üsküdar University and the Unifon-Biotech GSYF Venture Capital Investment Fund. The company is focused on translating Türkiye's capabilities in genomic engineering and synthetic biology into internationally competitive gene therapies for rare genetic diseases. Its lead program is an investigational adeno-associated virus (rAAV)-based micro-dystrophin gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD). To support its pipeline, Synastra has partnered with Swiss biotech NewBiologix to utilize their Xcell Stable Manufacturing Platform to establish a scalable, reproducible, and genetically defined production system early in development.